FDA’s Disparate Treatment Of Fibrinogen Products ‘Defies Logic,’ Octapharma Contends

 
• By Brenda Sandburg
  
Blood cells
US FDA sued over its classification of fibrinogen blood products • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Legal & IP

More from Pink Sheet